Ocugen announced positive 12-month data from its OCU410 Phase 2 trial showing significant reduction in lesion growth for geographic atrophy, supporting a Phase 3 trial planned for late 2026. The company completed enrollment for key trials in retinitis pigmentosa and Stargardt disease, aiming for Biologics License Application submissions by 2027. Ocugen also priced a $115 million convertible senior notes offering, expected to extend its cash runway into 2028 after retiring higher-interest debt. These developments position Ocugen for potential regulatory approvals and commercialization of its gene therapies targeting blindness diseases.
Equinor ASA will begin the third tranche of its 2026 share buy-back program on July 23, 2026, with purchases up to USD 371.3 million, contributing to a total tranche value of USD 1.125 billion including shares redeemed from the Norwegian State. This ...
Equinor ASA announced a cash dividend of $0.39 per share for the second quarter of 2026. The important dates include the last day inclusive on November 12, 2026, ex-dividend dates on November 13 (Oslo) and November 16 (NYSE), with the record date als...
Equinor ASA will begin the third tranche of its 2026 share buyback program on July 23, 2026, with a budget of up to $1.125 billion. This tranche includes $371.3 million worth of shares to be bought from the market and will conclude by October 26, 202...
Enigmatig Limited has invested in 'KUNGFULAND,' the first scripted feature-length action-comedy co-produced by Singapore and Canada using virtual production technology. The film, shot in Singapore, pays homage to 1970s Hong Kong martial arts cinema a...
Enigmatig Limited has invested in KUNGFULAND, the first scripted feature-length action-comedy co-produced by Singapore and Canada using virtual production technology. Filming began in June 2026 in Singapore, blending advanced LED wall technology with...
